Table 4.
Univariable logistic regression analysis for the predictors of proteinuria.
| Variables | Category | PU incidence (%) | Odds ratio (95%CI) | P-value |
|---|---|---|---|---|
| Demographics and clinical characteristics | ||||
| Gender | Male/Female | 77.66/73.24 | 1.27 (0.62–2.60) | 0.512 |
| Age at Tx (years) | ≥60/18–59 | 83.87/73.88 | 1.84 (0.66–5.16) | 0.247 |
| Previous kidney Tx | y/n | 81.58/74.01 | 1.67 (0.74–3.73) | 0.215 |
| Donor types | Non–/living donor | 75.25/76.56 | 0.93 (0.45–1.94) | 0.848 |
| Cold ischemia time (h) | ≥12/ <12 h | 65.22/83.64 | 0.37 (0.14–0.94) | 0.036 |
| HLA mismatches | ≥3/0–2 | 78.09/71.70 | 1.46 (0.71–3.03) | 0.308 |
| Peak PRA ≥5% | y/n | 91.43/71.54 | 4.42 (1.28–15.32) | 0.019 |
| Pre–Tx PRA ≥5% | y/n | 89.47/73.97 | 2.99 (0.66–13.55) | 0.155 |
| Delayed graft function | y/n | 88/71.3 | 2.95 (1.14–7.63) | 0.025 |
| Baseline Cr (mg/dL) | ≥1.5/1–1.5 | 80.68/68.12 | 1.01 (0.50–2.07) | 0.974 |
| Time from Tx to Bx (m) | ≥60/0–60 | 77/73.85 | 1.19 (0.58–2.44) | 0.644 |
| SBP (mmHg) | ≥140/90–140 | 85.54/63.52 | 3.07 (1.43–6.58) | 0.004 |
| DBP (mmHg) | ≥90/50–90 | 92.16/68.42 | 5.36 (1.80–15.93) | 0.003 |
| PTDM | y/n | 12.00/2.5 | 5.32 (0.68–41.60) | 0.111 |
| Calcineurin inhibitors | Tac/CyA | 81.13/66.67 | 2.15 (0.99–4.66) | 0.052 |
| Antiproliferative agents | MMF/MPA | 74.16/77.78 | 1.18 (0.61–2.29) | 0.617 |
| Steroid–free regimen | y/n | 75/75.94 | 1.05 (0.43–2.57) | 0.911 |
| BMI | ≥25/ | 75/77.66 | 0.86 (0.42–1.80) | 0.694 |
| Cr at the time of Bx (mg/dL) | ≥1.5/1–1.5 | 76.82/64.29 | 1.84 (0.58–5.85) | 0.301 |
| Age at Bx (years) | ≥60/18–59 | 83.02/72.32 | 1.87 (0.82–4.28) | 0.138 |
| Anti–HLA DSA | y/n | 74.19/80.49 | 0.70 (0.29–1.67) | 0.417 |
| Anti–hypertension agents*** | ||||
| ACEI/ARB | y/n | 79.34/65.91 | 1.99 (0.93–4.26) | 0.078 |
| Beta–adrenergic blockers | y/n | 79.69/73.27 | 1.48 (0.71–3.09) | 0.302 |
| Calcium channel blockers | y/n | 85.71/67.05 | 2.95 (1.36–6.37) | 0.006 |
| Etiology | ABMR/iTG | 73.81/82.05 | 0.67 (0.28–1.59) | 0.358 |
| Banff lesion scores | ||||
| i score | ≥1/0 | 73.86/77.92 | 0.80 (0.39–1.64) | 0.544 |
| t score | ≥1/0 | 75/76.03 | 0.95 (0.43–2.10) | 0.891 |
| v score | ≥1/0 | 63.64/76.62 | 0.53 (0.15–1.93) | 0.338 |
| g score | ≥1/0 | 72.84/78.57 | 0.73 (0.36–1.50) | 0.391 |
| ptc score | ≥1/0 | 81.03/72.90 | 1.59 (0.73–3.48) | 0.246 |
| C4d | ≥1/0 | 87.88/72.73 | 2.72 (0.89–8.28) | 0.078 |
| ci score | ≥1/0 | 77.32/73.53 | 1.23 (0.60–2.52) | 0.576 |
| ct score | ≥1/0 | 75/76.92 | 0.90 (0.43–1.87) | 0.778 |
| cv score | ≥1/0 | 76.38/73.68 | 1.16 (0.50–2.65) | 0.734 |
| cg score | ≥2/1 | 79.51/65.12 | 2.08 (0.97–4.47) | 0.061 |
| ah score | ≥1/0 | 75.97/72.73 | 1.19 (0.30–4.70) | 0.808 |
| mm score | ≥1/0 | 79/70.77 | 1.55 (0.76–3.19) | 0.230 |
Univariable logistic regression analysis was used to select possible predictors of proteinuria (PU ≥0.3 g/24 h). Incidence of PU was shown in different categories TG patients. P-values indicated the significance associated with proteinuria. CI, confidence interval; iTG, isolated transplant glomerulopathy. Bold values indicated statistical significance.
***
More than 6 consecutive months treatment before biopsy.